Results 121 to 130 of about 5,123 (202)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.

Am J Nephrol, 2022
Agarwal R, Anand S, Eckardt KU, Luo W, Parfrey PS, Sarnak MJ, Solinsky CM, Vargo DL, Winkelmayer WC, Chertow GM.   +9 more
europepmc   +1 more source

Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation

Case Reports in Hematology
Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched ...
Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza   +7 more
doaj   +1 more source

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

Cancer Management and Research, 2016
Jean-Loup Mouysset,1 Beata Freier,2 Joan van den Bosch,3 Charles Briac Levaché,4 Alain Bols,5 Hans Werner Tessen,6 Laura Belton,7 G Chet Bohac,8 Jan-Henrik Terwey,9 Giuseppe Tonini101Department of Medical Oncology, Clinique Rambot Provencale, Aix ...
Mouysset JL, Freier B, van den Bosch J, Levaché CB, Bols A, Tessen HW, Belton L, Bohac GC, Terwey JH, Tonini G   +9 more
doaj  

The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. [PDF]

Indian J Hematol Blood Transfus, 2022
Ak MA, Sahip B, Geduk A, Ucar MA, Kale H, Hacibekiroglu T, Polat MG, Kalpakci Y, Bolaman AZ, Guvenc B, Ertop S.   +10 more
europepmc   +1 more source

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.

Am J Nephrol, 2021
Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y.   +3 more
europepmc   +1 more source

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. [PDF]

Clin Exp Nephrol, 2021
Hayashi T, Kato H, Tanabe K, Nangaku M, Hirakata H, Wada T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I.   +19 more
europepmc   +1 more source

Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis

Journal of Blood Medicine, 2012
Ashraf MikhailRenal Unit, Morriston Hospital, Swansea University, Wales, UKAbstract: Peginesatide is a synthetic, dimeric peptide that is covalently linked to polyethylene glycol (PEG).
Mikhail A
doaj  

Safety, Tolerability, and Immunogenicity of Prescribed Usage of Darbepoetin-Alfa (Hetero Biopharma) in Patients of Chronic Kidney Disease With Renal Anemia: A Post-Marketing Surveillance Study. [PDF]

Cureus, 2021
Sinha SD, Bandi VK, Reddy BB, Thakur P, Chary S, Talluri L, Kakkunnath S.   +6 more
europepmc   +1 more source

Testing for recombinant human erythropoietin [PDF]

, 2008
Delanghe, Joris, Joyner, Michael
core   +1 more source

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP^®) Biosimilar, to Those of NESP^® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects. [PDF]

Drug Des Devel Ther, 2021
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S.   +7 more
europepmc   +1 more source